FDA’s one-day inspection pilot: what to expect

The U.S. Food and Drug Administration (FDA) on May 6^th, 2026, announced that it is piloting one-day inspectional assessments, as part of a broader initiative to make its inspectional resources more targeted and efficient. The pilot program has quietly already been initiated. In essence FDA conducts shorter and more focused screening assessments to complement the traditional FDA inspections. These assessments will be applicable for lower risk establishments. Establishment risk is based on product type, inspection history and operational characteristics. At this point the pilot does not apply to establishments performing high-risk and complex operations.

The program covers several FDA inspectorates such as human and animal drugs, biologics, medical devices and clinical research. However, the FDA has not published any SOPs, Federal Register notices, or inspection protocols for these types of assessments.

According to the FDA these assessments will enable the agency to assess more facilities and focus on critical aspects. The intention is not to replace the standard inspections but serves as an additional tool. When significant observations are made the assessments can be extended beyond one day.  The one-day assessments can still result in Form FDA 483 observations, warning letters or other enforcement actions.

As of April 2026, FDA conducted 46 one-day assessments, and the pilot will continue for the rest of 2026. Evaluation metrics are being developed to assess the effectiveness of this approach.

Considerations and takeaways

• What impact will these assessments have on the existing mutual recognition agreements between FDA and other regulatory agencies?
  
  

• The one-day assessments are performed with short notice, or even unannounced. It is important for establishments to ensure readiness by, for example, always ensure audit ready records and personnel.
  
  

• Having a low-risk status could be a competitive advantage. Establishments with strong compliance history and well-functioning quality systems are more likely to qualify for these shorter assessments, meaning possible decreased operational disruption.

The standards remain the same, but the one-day assessment should be considered a modernization of how FDA allocates resources and evaluate compliance risks. For regulated entities need to continue demonstrating compliance but with less preparation time and fewer opportunities to address deficiencies. Those establishments who can prove a strong compliance culture will possibly benefit from this approach.